MSLN and familial pancreatic carcinoma: The extensive review of the literature done by Czaplicka et al. (2024) identified a limited number of completed clinical trials investigating CAR-T therapy for pancreatic cancer with published data of Phase I studies exploring targets such as MSLN, EGFR, HER2, CLDN18.2 and have revealed both promise and significant challenges in their therapeutic application [68].